Sanofi/Regeneron’s PSCK9 Inhibitor Alirocumab Passes First Phase III Test
This article was originally published in The Pink Sheet Daily
Executive Summary
PCSK9 inhibitor alirocumab outperforms Merck’s Zetia as a monotherapy in first Phase III trial reported, a result that has relevance for the large population of statin-intolerant patients, according to the drug’s sponsors.